Australia's Resonance Health eyes best day in over 2-mths on TGA approval

Resonance Health

18/02/2021 03:14

** Shares of medical imaging software developer  RHT.AX 
jump as much as 43.6% to A$0.280, their biggest intraday
percentage gain since Dec. 9, 2020
    ** Co says it received Australian Therapeutic Goods
Administration (TGA) approval for HepaFat-AI, its fully
automated artificial intelligence (AI) software that assesses
liver fat  urn:newsml:reuters.com:*:nGLF2k2LVK
    ** Says TGA approval allows it to supply the software in
Australia
    ** RHT says it obtained U.S. Food & Drug Administration
(FDA) clearance for its AI software in Dec. 2020 
    ** Stock hits its highest level since Dec. 10, 2020
    ** Nearly 4.4 mln shares change hands compared with their
30-day average volume of ~585,200
    ** Stock down 18.8% this year, as of last close
    
  

 (Reporting by Vasudha Kaukuntla in Bengaluru)
 ((Vasudha.Kaukuntla@thomsonreuters.com))